Logos Global Management’s Neurocrine Biosciences NBIX Stock Holding History

Logos Global Management’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-150,000	Closed	-$18.9M	–	68
2025 Q2	$18.9M	Buy	+150,000	New	+$17.2M	2.09%	16
2025 Q1	–	Sell	-200,000	Closed	-$27.3M	–	51
2024 Q4	$27.3M	Buy	+200,000	New	+$24.7M	3.19%	11
2023 Q4	–	Sell	-150,000	Closed	-$16.9M	–	64
2023 Q3	$16.9M	Sell	150,000 -150,000	-50%	-$15.8M	2.25%	15
2023 Q2	$28.3M	Buy	300,000 +100,000	+50%	+$9.77M	3.85%	9
2023 Q1	$20.2M	Buy	+200,000	New	+$20.8M	2.9%	12
2022 Q3	–	Sell	-300,000	Closed	-$29.2M	–	43
2022 Q2	$29.2M	Sell	300,000 -175,000	-37%	-$16.2M	5.37%	6
2022 Q1	$44.5M	Buy	+475,000	New	+$40.3M	5.77%	5

Other funds holding NBIX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Logos Global Management's NBIX Position: Q3 2025 in Review

Logos Global Management sold out of Neurocrine Biosciences (NBIX) in Q3 2025, closing a stake of 150,000 shares — an estimated $18.9M sold.

Logos Global Management first reported a position in NBIX in Q1 2022 and held it in 7 quarters. The position peaked at $44.5M in Q1 2022. 649 funds tracked by Wall St. Rank hold NBIX as of Q3 2025.

Logos Global Management reported no remaining Neurocrine Biosciences position as of Q3 2025 after selling out during the quarter.
Logos Global Management sold 150,000 Neurocrine Biosciences shares in Q3 2025, an estimated $18.9M.
Logos Global Management first reported a position in Neurocrine Biosciences in Q1 2022 and held it in 7 quarters.
Logos Global Management's Neurocrine Biosciences position peaked at $44.5M in Q1 2022.
649 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q3 2025.

Based on Logos Global Management's 13F filing for Q3 2025, filed 14 Nov 2025.